AcrySof™ IQ PanOptix™ Toric UV IOL TFAT50 (REF TFAT50.310)Recalls & reported problems
Alcon Laboratories, Inc. · AcrySof® IQ PanOptix® Toric Trifocal intraocular lenses (IOLs) are ultraviolet absorbing foldable multifocal IOLs · Class 3 · Implant
All models of AcrySof IQ PanOptix Toric UV IOL (120)
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 00380652419970), received between Jun 6, 2022 and Jun 6, 2022 — classified as 1 injury.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem1
Patient problems
- Blurred Vision1
- Visual Disturbances1
- Visual Impairment1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
InjuryJun 6, 2022Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
A PHYSICIAN REPORTED THAT FOLLOWING AN INTRAOCULAR LENS (IOL) IMPLANT PROCEDURE, A PATIENT HAS OVER 1D OF RESIDUAL CYL POST OP. ADDITIONAL INFORMATION WAS RECEIVED STATING IN POST OP AFTER 7 DAYS OF SURGERY THE PATIENT HAS NOTICED BLURRED VISION AND PHOTOPHOBIA IN THE AFFECTED EYE. THE PATIENT WAS TAKING CORTICOSTEROIDS AND ANTIBIOTIC MEDICINE. THE PSEUDOPHAKIC IOL WAS CENTERED AND POSTERIOR CAPSULE OPACIFICATION WELL CENTERED. THIS PATIENT HAS HAD A REFRACTIVE SURPRISE. ALTHOUGH ANATOMICALLY THE SURGERY LOOKS GOOD, HER VISION WAS NOT ACCEPTABLE. IN POST OP 15 DAYS OF SURGERY THE PATIENT WAS HEALING WELL AFTER CATARACT SURGERY. UNFORTUNATELY SHE HAS A REFRACTIVE SURPRISE. SHE STARTED OUT WITH APPROXIMATELY 4 1/2 DPT OF CORNEAL ASTIGMATISM ON THE LEFT AND THAT DOWN TO ABOUT 1.25. IN ADDITION SHE WAS SOMEWHAT NEARSIGHTED.
Patient problems: Blurred Vision; Visual Disturbances; Visual Impairment
MAUDE report 14604589 ↗
Other Lens, multifocal intraocular devices
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular144 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular1 recall66 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular113 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular112 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular110 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular107 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular104 reports
- Clareon™ CNA0T0Alcon Laboratories, Inc. · Lens, multifocal intraocular93 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page